Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

ANJESO

MELOXICAM

Standard Dose
30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview ANJESO is listed in Drugs@FDA under application 210583 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient MELOXICAM Form and strength SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUDAX Submission history Latest submission status date: 2021-07-15 00:00:00.

Structured Monograph

Clinical summary

Approval overview ANJESO is listed in Drugs@FDA under application 210583 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MELOXICAM Form and strength SOLUTION;INTRAVENOUS - 30MG/ML (30MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor BAUDAX Submission history Latest submission status date: 2021-07-15 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.